3.3.2 Nebulised Mucolytics
There is no locally commissioned nebuliser service, so patients must self-fund the nebuliser equipment and maintenance costs.
It is essential that patients are assessed as having a strong enough cough to be able to expectorate following nebulisation.
Different strengths of sodium chloride can be used to help clear secretions from the airways.
Dornase alfa and mannitol
Only for use in cystic fibrosis patients; prescribed by the specialist centre. See chapter 3.5.1 for more information.
This strength may be used in primary care without a challenge test in view of low risk of bronchospasm.
| Pack |
|---|
| 20 vial |
For use where 7% solution is not tolerated and for cases of bronchiolitis.
Suitable for GP prescribing only after challenge testing in secondary care due to risk of significant bronchospasm.
Treatment option for mucus consolidation e.g. in cystic fibrosis, suppurative lung disease, bronchiolitis in adults and children from 6 years.
There is little evidence to support the use of this treatment in the under 6’s.
| Pack |
|---|
| 20 ampoule |
Suitable for GP prescribing only after challenge testing in secondary care due to risk of significant bronchospasm.
Treatment option for mucus consolidation e.g. in cystic fibrosis, suppurative lung disease, bronchiolitis in adults and children from 6 years.
There is little evidence to support the use of this treatment in the under 6’s.
| Pack |
|---|
| 60 vial |
May be used in specialist secondary care services such as Intensive Care and the specialist respiratory wards.
| Pack |
|---|
| 10 ampoule |
- First Line Drugs
- Second Line Drugs
- Specialist Initiated or Recommended Drugs
- Specialist Initiated Drugs with Shared Care Guidelines
- Specialist Only Drugs
- Mixed Status